Last reviewed · How we verify
RAR Gamma
At a glance
| Generic name | RAR Gamma |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) (PHASE2)
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (PHASE3)
- An Efficacy and Safety Study of Palovarotene for the Treatment of MO (PHASE2)
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects (PHASE2)
- In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects (PHASE2)
- TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAR Gamma CI brief — competitive landscape report
- RAR Gamma updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI